Telaprevir Enhances Ribavirin-Induced Anaemia through Renal Function Impairment

Abstract

Background

Alterations in renal function have been described with telaprevir (TVR). We examined the relationship between ribavirin (RBV) trough concentration (C), estimated glomerular filtration rate (eGFR) and severe anaemia, before and after TVR introduction in HIV–HCV-coinfected patients included in ANRS HC26 TelapreVIH study.

Methods

69 HIV–HCV genotype-1 coinfected patients received 4 weeks of pegylated interferon (PEG-IFN)-α2a/RBV, followed by 12 weeks of TVR/PEG-IFN/RBV, then 32 to 56 weeks of PEG-IFN/RBV. RBV C was determined at week (W)4, W8 and W20/24. eGFR was estimated by the Modification of the Diet in Renal Disease (MDRD) equation. Severe anaemia was defined as haemoglobin <70 g/l, RBV dose reduction, prescription of erythropoietin or blood transfusion.

Results

67 patients were analysed. eGFR remained normal between baseline (97.9 ml/min) and W4 (103.4 ml/min), declined to 86.3 ml/min at W8 (P<0.0001), stabilized until W16 and increased back to baseline level at W20 (98.4 ml/min). RBV C increased from 1.88 mg/l at W4 to 2.88 mg/l at W8 (P<0.0001), then decreased to 2.73 mg/l at week 20/24 (P=0.015). An inverse correlation was observed between W8 eGFR and W8 RBV C (r2=0.429; P=0.0005). RBV C≥3 mg/l was observed in 12% of patients at W4, 45% at W8 (P<0.0001) and 38% at W20/24 (P=0.0005). Severe anaemia was observed in 23.9% of patients at W4 and 45.3% at W8. RBV C≥3 mg/l at W8 (OR 7.7 [95% CI 2.2, 27.4]) and baseline haemoglobin <150 g/l (OR 6.4 [1.7, 23.8]) were independently associated with W8 severe anaemia.

Conclusions

Association of TVR to PEG-IFN/RBV was associated with a decrease in eGFR and increase in RBV C, leading to severe anaemia in 45% of patients.

References

Bacon

B.R.

, Gordon

S.C.

, Lawitz

Boceprevir for previously treated chronic HCV genotype 1 infection.

N Engl J Med 2011; 364: 1207–1217.

Jacobson

I.M.

, McHutchison

J.G.

, Dusheiko

Telaprevir for previously untreated chronic hepatitis C virus infection.

N Engl J Med 2011; 364: 2405–2416.

Poordad

, McCone

Jr. , Bacon

B.R.

Boceprevir for untreated chronic HCV genotype 1 infection.

N Engl J Med 2011; 364: 1195–1206.

Zeuzem

, Andreone

, Pol

Telaprevir for retreatment of HCV infection.

N Engl J Med 2011; 364: 2417–2428.

Sitole

, Silva

, Spooner

, Comee

M.K.

, Malloy

Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from Phase II and III trials.

Clin Ther 2013; 35: 190–197.

Borroni

, Cazzaniga

, Andreoletti

Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C.

J Viral Hepat 2013; 20: e90–e95.

Glue

The clinical pharmacology of ribavirin.

Semin Liver Dis 1999; 19 Suppl 1: 17–24.

Gupta

S.K.

, Kantesaria

, Glue

Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients.

Eur J Clin Pharmacol 2012; 68: 415–418.

Gupta

S.K.

, Kantesaria

, Glue

Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing.

Drug Discov Ther 2014; 8: 89–95.

10.

Kramer

T.H.

, Gaar

G.G.

, Ray

C.G.

, Minnich

, Copeland

J.G.

, Connor

J.D.

Hemodialysis clearance of intravenously administered ribavirin.

Antimicrob Agents Chemother 1990; 34: 489–490.

11.

Cotte

, Braun

, Lascoux-Combe

Telaprevir for HIV-HCV coinfected patients failing peginterferon-ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.

Clin Infect Dis 2014; 59: 1768–1776.

12.

Rendón

A.L.

, Nunez

, Romero

Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients.

J Acquir Immune Defic Syndr 2005; 39: 401–405.

13.

Brochot

, Castelain

, Duverlie

, Capron

, Nguyen-Khac

, Francois

Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.

Antivir Ther 2010; 15: 687–695.

14.

Chevaliez

, Hezode

, Soulier

High-dose pegylated interferon-alpha and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).

Gastroenterology 2011; 141: 119–127.

15.

Levey

A.S.

, Bosch

J.P.

, Lewis

J.B.

, Greene

, Rogers

, Roth

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Ann Intern Med 1999; 130: 461–470.

16.

Levey

A.S.

, Eckardt

K.U.

, Tsukamoto

Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

Kidney Int 2005; 67: 2089–2100.

17.

Karino

, Ozeki

, Hige

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C.

J Viral Hepat 2014; 21: 341–347.

18.

Karino

, Hige

, Nakajima

Telaprevir induced renal dysfunction leads to an early elevation of serum ribavirin concentration in triple therapy.

Hepatology 2012; 56 Suppl 1: 1005A–1006A.

19.

Tempestilli

, D'Offizi

, Lionetti

Increased plasma concentration of ribavirin as a result of renal dysfunction in HCV patients treated with telaprevir.

Hepatology 2014; 60: 1109–1110.

20.

Mauss

, Hueppe

, Alshuth

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.

Hepatology 2014; 59: 46–48.

21.

Fukuda

, Imai

, Hiramatsu

Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C.

Hepatol Res 2014; 44: 1165–1171.

22.

Kunze

, Huwyler

, Camenisch

, Gutmann

Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters.

Biochem Pharmacol 2012; 84: 1096–1102.

23.

Meyer zu Schwabedissen

H.E.

, Verstuyft

, Kroemer

H.K.

, Becquemont

, Kim

R.B.

Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.

Am J Physiol Renal Physiol 2010; 298: F997–F1005.

24.

Nakada

, Kito

, Inoue

Evaluation of the potency of telaprevir and its metabolites as inhibitors of renal organic cation transporters, a potential mechanism for the elevation of serum creatinine.

Drug Metab Pharmacokinet 2014; 29: 266–271.

25.

Gervasoni

, Milazzo

, Pezzani

, Fucile

, Cattaneo

Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.

AIDS 2014; 28: 285–287.

26.

Hall

A.M.

Update on tenofovir toxicity in the kidney.

Pediatr Nephrol 2013; 28: 1011–1023.

27.

Ryom

, Mocroft

, Lundgren

HIV therapies and the kidney: some good, some not so good?

Curr HIV/AIDS Rep 2012; 9: 111–120.

28.

Sievert

, Dore

G.J.

, McCaughan

G.W.

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.

Hepatology 2011; 53: 1109–1117.

29.

Sulkowski

M.S.

, Shiffman

M.L.

, Afdhal

N.H.

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.

Gastroenterol 2010; 139: 1602–1611.

30.

Maynard

, Gagnieu

M.C.

, Pradat

, Souvignet

, Trepo

Prediction of sustained virological response by ribavirin plasma concentration at week 4 during pegylated-interferon/ribavirin combination therapy in HCV patients.

J Hepatol 2007; 46: S234.

31.

van Vlerken

L.G.

, van Oijen

M.G.

, van Erpecum

K.J.

Ribavirin concentration is a more important predictor of sustained viral response than anemia in hepatitis C patients.

Gastroenterol 2011; 140: 1693–1694.

32.

Garg

, Kauffman

R.S.

, Beaumont

, van Heeswijk

R.P.

Telaprevir: pharmacokinetics and drug interactions.

Antivir Ther 2012; 17: 1211–1221.

33.

Aghemo

, Grassi

, Rumi

M.G.

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir.

PLoS ONE 2014; 9: e95881.

34.

EASL. Recommendations on Treatment of Hepatitis C. 2014. (Accessed 29 August 2014.) Available from http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf.

35.

Hoofnagle

J.H.

, Sherker

A.H.

Therapy for hepatitis C–the costs of success.

N Engl J Med 2014; 370: 1552–1553.

36.

Brennan

B.J.

, Wang

, Blotner

Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.

Antimicrob Agents Chemother 2013; 57: 6097–6105.

37.

C.C.

, Weng

C.H.

, Lin

C.L.

Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-alpha.

Ren Fail 2012; 34: 429–434.

38.

Akamatsu

, Hayes

C.N.

, Tsuge

Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.

J Viral Hepat 2015; 22: 166–174.

39.

Roberts

S.K.

, Andreone

, Pol

Impact of anemia and ribavirin dose reduction on SVR in a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the Phase III REALIZE study.

Hepatology 2011; 54: 1007A–1008A.

40.

Sulkowski

M.S.

, Reddy

, Afdhal

N.H.

Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE Phase 3 Studies.

J Hepatol 2011; 54: S195.